Interpace Biosciences announces extension of Medicare coverage for PancraGEN

Interpace Diagnostics responded to the undefined extension granted by Centers for Medicare & Medicaid Services to Novitas, its Medicare Administrative Contractor. Novitas announced late last week that CMS granted an extension to the final decision for Local Coverage Determination of Genetic Testing for Oncology in order for all comments received in response to the proposed changes to be thoroughly considered. LCD includes PancraGEN, a DNA-based diagnostic molecular test. It uniquely assesses the risk of pancreatic cyst progression to cancer by integrating the results of first-line tests and procedures with molecular test results.